Germline polymorphism of p53 codon 72 in gynecological cancer

Ueda, Masatsugu; Terai, Yoshito; Kanda, Koji; Kanemura, Masanori; Takehara, Mikio; Yamaguchi, Hiroyuki; Nishiyama, K.; Yasuda, Masayuki; Ueki, Minoru

doi:10.1016/j.ygyno.2005.08.015

Cited by 42 publications

(40 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The significance of pooled OR in all-individuals analysis and subgroup analysis was not substantially influenced by omitting any single study. Furthermore, we also performed a sensitivity analysis by omission of one non-HWE study (Ueda et al, 2006). There was also no obvious influence on all-individuals analysis and subgroup analysis.…”

Section: Main Results Subgroup and Sensitivity Analysismentioning

confidence: 99%

“…According to the inclusion criteria, only 10 case-control studies (Esteller et al, 1997;Peller et al, 1999;Agorastos et al, 2004;Roh et al, 2004;Niwa et al, 2005;Ueda et al, 2006;Ashton et al, 2009;Nunobiki et al, 2009;Zubor et al, 2009;Ghasemi et al, 2010) with full-text were included in this meta-analysis and 21 studies were excluded. The flow chart for the study selection is summarized in Figure 1.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

“…Diverse genotyping methods were mainly used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and -direct sequencing (PCR-DS). The HWE test was performed on all included studies, all of them were shown to be in HWE (P > 0.05) except one by Ueda et al (2006). The baseline characteristics and methodological quality of all included studies are summarized in Table 1.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

See 2 more Smart Citations

Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk

Zhou²,

Zhang³

2011

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Polymorphisms of the p53 gene have been associated with susceptibility to endometrial cancer. However, whether there is a specific association is still controversial. We investigated a possible association between p53 codon 72 polymorphism and endometrial cancer risk by conducting a meta-analysis. Publications addressing this association were selected from the Pubmed, Embase and CBM databases (up to January 2011). Data were extracted from the studies by two independent reviewers. The meta-analysis was performed using RevMan 5.0.25 and STATA 9.2 softwares. The odds ratio (OR) with 95% confidence intervals (CI) was calculated. Then, 10 casecontrol studies were retrieved, with a total of 917 endometrial cancer patients and 1680 healthy controls. Meta-analysis results showed that the Pro allele and Pro carrier (Arg/Pro + Pro/Pro) of p53 codon 72 polymorphism were significantly related with endometrial cancer risk (OR = 1.25, 95%CI = 1.10-1.41, P = 0.0005; OR = 1.34, 95%CI = 1.12-1.59, P = 0.001, respectively). In the subgroup analysis, based on ethnicity, studies were divided into Asian and Caucasian populations; the Pro allele and Pro carrier (Arg/Pro + Pro/Pro) of p53 codon 72 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 10 (4): 3609-3619 (2011) Y. Gu et al. 3610 polymorphism were significantly related with endometrial cancer risk in Asian populations (OR = 1.41, 95%CI = 1.19-1.66, P < 0.0001; OR = 1.66, 95%CI = 1.30-2.13, P < 0.0001, respectively), but not in Caucasian populations (both P > 0.05). We concluded that the Pro allele (Arg/Pro + Pro/Pro) of p53 codon 72 polymorphism is a potential risk factor for endometrial cancer.

show abstract

Section: Main Results Subgroup and Sensitivity Analysismentioning

confidence: 99%

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk

Zhou²,

Zhang³

2011

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Ashton et al (Ashton et al, 2009) showed no effect of the TP53 polymorphism and MDM2 SNP309 alone or in combination with endometrial cancer risk. The status of the TP53 gene (wild-type or mutant type) is critical when determining the relationship between grade and a TP53 polymorphism (Hui et al, 2005;Oda et al, 2005;Ueda et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

Polymorphism of p53 Gene Codon 72 in Endometrial Cancer: Correlation with Tumor Grade and Histological Type

Kafshdooz¹,

Tabrizi²,

Ardabili³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Endometrial cancer is the fourth most common cancer among women in developed countries. Patients with endometrial cancer may benefit from systemic chemotherapy alone or in combination with targeted therapies if the disease is clinically diagnosed prior to spread and metastasis to other organs. The aim of this study was to evaluate the prognostic role of p53 polymorphism and its correlation with tumor grade in human uterine endometrial carcinomas. Materials and Methods: A total of 75 patients with endometrial carcinomas were studied for possible mutations in exon 4 of the p53 gene using polymerase chain reaction and restricting fragment length polymorphism techniques and sequencing. Results: In recent study, The rate of homozygote genotype of pro/pro or Arg/Arg in high grade group was higher than in comparison with low grade one. In addition samples that were undigested in RFLP, showed mutation in exone 4. Conclusions: Our findings showed that high grade endometrial carcinomas are highly associated with TP53 polymorphisms in comparison with low grades.

show abstract

“…However, most of these studies had a small sample size for the ovarian cancer cases (about 300 and below). In particular, most of the studies of genetic (Aktas et al 2002) 117/202 Hospital Turkey CYP1A1 gene (Qie et al 2002) 15/20 Hospital China p53 codon 72 polymorphism (Li et al 2002) 39/131 Hospital China p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus (Sugawara et al 2003) 46/31 Hospital Japan CYP1A1 polymorphism (Kang et al 2004) 124/128 Hospital China p53 codon 72 and p53 intron 3 (PIN3) polymorphism (Kang et al 2004) 257/257 Hospital China Microsomal epoxide hydrolase polymorphism (Ueda et al 2006) 68/95 Hospital Japan p53 codon 72 polymorphism (Li et al 2006) 122/138 Hospital China The promoter region of the matrix metalloproteinases-1 -1607bp1G/2G, matrix metalloproteinases-3 -1171bp5A/6A, matrix metalloproteinases-7 A-181G and matrix metalloproteinases-9 C-1562T (Yang et al 2006) 202/266 Hospital China Single nucleotide polymorphisms (SNPs) Thr307Ala and Asn680Ser (Jo et al 2007) 94/329 Hospital Korea The C19007T polymorphism of ERCC1 (Zhang et al 2008) 56/20 Hospital China Tissue samples, mismatch repair gene hMLH1 and hMSH2 (Li et al 2008) 207/256 Hospital China The -160C/A, -347G/GA polymorphism within the promoter region and 3'-UTR +54C/T polymorphism of E-cadherin 96/115 Hospital China Interleukin-23 receptor gene polymorphisms (Li et al 2010) 303/303 Hospital China VEGF gene polymorphisms (Liu F 2010) 34/45 Hospital China CYP1A1 Ile/Val polymorphisms (ZY et al 2010) 78/90 Hospital China CYP1A1 gene polymorphism (Ma et al 2011) 218/285 Hospital China CASP8 gene…”

Section: Discussionmentioning

confidence: 99%

Korean Epithelial Ovarian Cancer Study (Ko-EVE): Protocols and Interim Report

Hyun¹,

Kim²,

Choi³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: There have been few studies of Asian ovarian cancer and benign tumors. The primary aim of this paper was to report the protocol of the Ko-EVE study to examine epidemiological and molecular factors for ovarian cancer and benign neoplasms and to ascertain the major risk factors for ovarian cancer control in Korea. Methods: This case-control study covers incident epithelial ovarian cancers and benign neoplasms, four major centers participating in enrolling incident cases and 3 hospitals enrolling healthy controls among health examinees. Standardized questionnaires were administered by trained interviewers, including sections on socio-demographics characteristics, past medical history, medication usage, family history, lifetime consumption of alcohol and tobacco, diet, physical activity, and reproductive factors for women. Various biological specimens were collected in the biorepository according to the standardized protocol. Annual follow-up for cancer cases and follow-up at the 1st year for benign tumor cases are performing to evaluate treatment effect and progression. Passive follow to see long-term survival will be conducting using record linkage with national data. Results: The total number recruited in 2010-2011 was 246 epithelial ovarian cancer cases, 362 benign epithelial tumors and 345 controls. We are planning to collect subjects for at least 1,500 sets of ovarian cancer, 2,000 benign tumors and 1,500 controls till 2018. Conclusion: The Ko-EVE will provide unique and important data to probe the etiology and natural history of Korean epithelial ovarian cancer. It will be continued by genomic and proteomic epidemiological analyses and future intervention studies for the prevention of ovarian cancer among Koreans.

show abstract

Germline polymorphism of p53 codon 72 in gynecological cancer

Cited by 42 publications

References 30 publications

Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk

Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk

Polymorphism of p53 Gene Codon 72 in Endometrial Cancer: Correlation with Tumor Grade and Histological Type

Korean Epithelial Ovarian Cancer Study (Ko-EVE): Protocols and Interim Report

Contact Info

Product

Resources

About